For patients with NRAS mutant melanoma, the median PFS was 3.0 and 5.1 months for nonsorafenib and sorafenib arms (p = 0.079), respectively, and the median OS was 9.8 and 10.3 months for nonsorafenib arms (n = 18) and sorafenib arms (n = 22; p = 0.506), respectively, the ORRs were 5.6 and 22.7% for nonsorafenib and sorafenib arms [350]. Here, NRAS is linked to melanoma.